Full Breakdown
ImmunityBio’s ANKTIVA + BCG Regimen Shows Superior Outcomes in Comparative Bladder-Cancer Analyses
5/20/2026, 12:45:45 PM
Core Findings: Higher Response Rates and Durability
ImmunityBio reported that its ANKTIVA combination therapy with bacillus Calmette-Guérin (BCG) achieved an “anytime” complete response (CR) rate of 69.7 percent in a matching-adjusted indirect comparison with nadofaragene firadenovec-vncg, whose CR rate was 53.4 percent. The median duration of complete response was 22.1 months for ANKTIVA + BCG, compared with 9.7 months for the gene-therapy comparator. In a separate indirect analysis versus TAR-200, the ANKTIVA regimen produced a 12-month CR rate of 49.2 percent versus 45.9 percent for TAR-200; the difference did not reach statistical significance.
Comparative Context: Trials and Methodology
The efficacy data for ANKTIVA + BCG were drawn from the QUILT-3.032 study, while the comparator data for nadofaragene firadenovec-vncg originated from its own pivotal trial. The comparison with TAR-200 used patient-level data from the SunRISe-1 trial. Both analyses employed a matching-adjusted indirect comparison (MAIC) approach to align baseline characteristics across studies, allowing a head-to-head assessment in the absence of a direct randomized trial.
Safety Outcomes: Reduced Treatment-Related Adverse Events
In the ANKTIVA + BCG cohort, 61.7 percent of patients experienced treatment-related adverse events, versus 83.5 percent in the TAR-200 group. ImmunityBio quantified this as a statistically significant 68 percent reduction in the odds of adverse events for patients receiving the ANKTIVA regimen. No safety comparison was provided for the nadofaragene firadenovec-vncg arm.
Official Statements from ImmunityBio
ImmunityBio’s release emphasized that “the analysis showed a statistically significant 68 percent reduction in the odds of treatment-related adverse events for patients treated with ANKTIVA plus BCG.” The company also highlighted the longer median CR duration and higher overall CR rate as evidence of the regimen’s clinical advantage.
Criticism, Limitations, and Gaps
The reports note that overall survival differences between ANKTIVA + BCG and the comparator therapies were not statistically significant. Additionally, the 12-month CR advantage over TAR-200 lacked statistical significance, and the indirect nature of the comparisons introduces uncertainty regarding unmeasured confounders. No independent external validation of the MAIC methodology was presented.
Implications for Bladder-Cancer Treatment Landscape
If confirmed in prospective head-to-head trials, the higher CR rates and more favorable safety profile of ANKTIVA + BCG could influence treatment selection for patients eligible for intravesical therapy. The data may also affect market dynamics, as clinicians weigh efficacy against adverse-event risk when choosing between gene-therapy, novel intravesical agents, and established BCG-based regimens.
What’s Next: Market Reaction and Further Evaluation
Following the announcement, ImmunityBio’s share price fell 3.94 percent to $7.97. The company indicated that additional clinical data and potential regulatory submissions are forthcoming, though specific timelines were not disclosed. Continued monitoring of real-world outcomes and forthcoming trial results will be essential to substantiate the comparative advantages reported in the current analyses.
